1. Home
  2. NAN vs PRTA Comparison

NAN vs PRTA Comparison

Compare NAN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAN
  • PRTA
  • Stock Information
  • Founded
  • NAN 1999
  • PRTA 2012
  • Country
  • NAN United States
  • PRTA Ireland
  • Employees
  • NAN N/A
  • PRTA N/A
  • Industry
  • NAN Investment Managers
  • PRTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAN Finance
  • PRTA Health Care
  • Exchange
  • NAN Nasdaq
  • PRTA Nasdaq
  • Market Cap
  • NAN 342.0M
  • PRTA 472.1M
  • IPO Year
  • NAN N/A
  • PRTA N/A
  • Fundamental
  • Price
  • NAN $10.97
  • PRTA $8.20
  • Analyst Decision
  • NAN
  • PRTA Buy
  • Analyst Count
  • NAN 0
  • PRTA 10
  • Target Price
  • NAN N/A
  • PRTA $14.86
  • AVG Volume (30 Days)
  • NAN 74.6K
  • PRTA 1.2M
  • Earning Date
  • NAN 01-01-0001
  • PRTA 08-04-2025
  • Dividend Yield
  • NAN 4.37%
  • PRTA N/A
  • EPS Growth
  • NAN N/A
  • PRTA N/A
  • EPS
  • NAN N/A
  • PRTA N/A
  • Revenue
  • NAN N/A
  • PRTA $10,341,000.00
  • Revenue This Year
  • NAN N/A
  • PRTA N/A
  • Revenue Next Year
  • NAN N/A
  • PRTA $389.77
  • P/E Ratio
  • NAN N/A
  • PRTA N/A
  • Revenue Growth
  • NAN N/A
  • PRTA N/A
  • 52 Week Low
  • NAN $9.11
  • PRTA $4.32
  • 52 Week High
  • NAN $11.34
  • PRTA $22.83
  • Technical
  • Relative Strength Index (RSI)
  • NAN 37.01
  • PRTA 58.73
  • Support Level
  • NAN $10.89
  • PRTA $8.05
  • Resistance Level
  • NAN $10.94
  • PRTA $8.73
  • Average True Range (ATR)
  • NAN 0.06
  • PRTA 0.38
  • MACD
  • NAN -0.00
  • PRTA -0.05
  • Stochastic Oscillator
  • NAN 33.33
  • PRTA 47.62

About NAN Nuveen New York Quality Municipal Income Fund

Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Share on Social Networks: